Tamsulosin

Generic Name: Tamsulosin

Brand Names: Flomax, Jalyn

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₈N_₂O_₅S

CAS Number: 106133-20-4

Unique Ingredient Identifier: G3P28OML5I

Background: Tamsulosin is a selective alpha-1A and alpha-1B adrenoceptor antagonist that exerts its greatest effect in the prostate and bladder, where these receptors are most common. It is indicated for the treatment of signs and symptoms of benign prostatic hypertrophy. Antagonism of these receptors leads to relaxation of smooth muscle in the prostate and detrusor muscles in the bladder, allowing for better urinary flow. Other alpha-1 adrenoceptor antagonists developed in the 1980s were less selective and more likely to act on the smooth muscle of blood vessels, resulting in hypotension.

Tamsulosin was first approved by the FDA on April 15, 1997.

Indication: Tamsulosin is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.

Tamsulosin is also used off label for the treatment of ureteral stones, prostatitis, and female voiding dysfunction.

Associated Conditions: Benign Prostatic Hyperplasia (BPH), Benign Prostatic Hypertrophy, Bladder Outlet Obstruction, Ureteral Calculus

Associated Therapies: -

Clinical Trials

Investigating Medication vs. Prostatic Urethral Lift: Assessment and Comparison of Therapies for BPH

Phase 4

Recruiting

Conditions: BPH

Interventions: Device: UroLift System
Drug: Tamsulosin Hydrochloride

First Posted Date: 2021-08-03

Last Posted Date: 2023-04-25

Lead Sponsor: NeoTract, Inc.

Target Recruit Count: 250

Registration Number: NCT04987892

Locations: 🇺🇸
Neotract, Pleasanton, California, United States

Pre-operative Tamsulosin and Time to Spontaneous Void After Hysterectomy

Phase 2

Completed

Conditions: Urinary Retention Postoperative

Interventions: Drug: Tamsulosin
Drug: Placebo

First Posted Date: 2021-04-26

Last Posted Date: 2024-02-29

Lead Sponsor: University of Arizona

Target Recruit Count: 161

Registration Number: NCT04859660

Locations: 🇺🇸
Banner University Medical Center- Phoenix, Phoenix, Arizona, United States
🇺🇸
Banner University Medical Center- Tucson, Tucson, Arizona, United States

Tamsulosin as Adjunctive Therapy After Extracorporeal Shock Wave Lithotripsy for Renal Stones

Phase 4

Completed

Conditions: Renal Stone

Interventions: Procedure: Extracorporeal shock wave lithotripsy
Drug: Diclofenac
Drug: Tamsulosin

First Posted Date: 2021-03-29

Last Posted Date: 2021-04-01

Lead Sponsor: Hospital Regional de Alta Especialidad del Bajio

Target Recruit Count: 60

Registration Number: NCT04819828

The Effect of Tamsulosin on Postoperative Urinary Retention

Phase 4

Terminated

Conditions: Urinary Retention

Interventions: Drug: Placebo
Drug: Tamsulosin

First Posted Date: 2020-12-23

Last Posted Date: 2024-01-31

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 4

Registration Number: NCT04682366

Locations: 🇺🇸
Wake Forest Health Sciences, Winston-Salem, North Carolina, United States

Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery

Phase 2

Recruiting

Conditions: Urinary Retention Postoperative

Interventions: Drug: Placebo
Drug: Tamsulosin

First Posted Date: 2020-10-22

Last Posted Date: 2024-01-22

Lead Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

Target Recruit Count: 154

Registration Number: NCT04597372

Locations: 🇺🇸
West Penn Hospital, Pittsburgh, Pennsylvania, United States

Chronic Prostatitis Collaborative Research Network Clinical Trial- Ciprofloxacin and Tamsulosin

Phase 2

Completed

Conditions: Chronic Prostatitis With Chronic Pelvic Pain Syndrome

Interventions: Drug: Ciprofloxacin
Drug: Tamsulosin Hydrochloride
Drug: Ciprofloxacin placebo
Drug: Tamsulosin Hydrochloride Placebo

First Posted Date: 2020-09-17

Last Posted Date: 2020-09-18

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 196

Registration Number: NCT04552431

Tamsulosin to Prevent Postoperative Urinary Retention in Laparoscopic Inguinal Hernia Repair

Phase 4

Terminated

Conditions: Post Operative Urinary Retention

Interventions: Drug: Placebo
Drug: Tamsulosin

First Posted Date: 2020-06-16

Last Posted Date: 2020-06-16

Lead Sponsor: Jewish Hospital, Cincinnati, Ohio

Target Recruit Count: 170

Registration Number: NCT04434378

Locations: 🇺🇸
Jewish Hospital, Cincinnati, Ohio, United States

Tamsulosin for Thyroid Lid Retraction

Not Applicable

Conditions: Thyroid Eye Disease
Eyelid Diseases

Interventions: Drug: Tamsulosin

First Posted Date: 2020-04-24

Last Posted Date: 2022-06-23

Lead Sponsor: Sheba Medical Center

Target Recruit Count: 50

Registration Number: NCT04359979

Locations: 🇮🇱
Sheba Medical Center, Tel Hashomer, Israel

Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms

Phase 3

Conditions: Ureteral Stent
Stent Related Symptoms

Interventions: Drug: Placebo oral tablet
Drug: Mirabegron 50 MG
Drug: Tamsulosin
Drug: Solifenacin Succinate 10 MG

First Posted Date: 2020-03-30

Last Posted Date: 2021-11-23

Lead Sponsor: Mansoura University

Target Recruit Count: 240

Registration Number: NCT04325880

Locations: 🇪🇬
Urology and Nephrology Center, Mansoura, DK, Egypt

REduction of Post-Operative Urinary Retention With Tamsulosin Versus Placebo (REPOURT- P) Trial

Phase 3

Conditions: Urinary Catheterization
Thoracic Surgery
Thoracic Epidural Analgesia

Interventions: Drug: Placebos
Drug: Tamsulosin Hydrochloride

First Posted Date: 2019-11-12

Last Posted Date: 2021-02-25

Lead Sponsor: McMaster University

Target Recruit Count: 350

Registration Number: NCT04159077

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy